Gate News message, April 21 — Wantai Biotech (603392) reported its first annual loss since listing in 2020, with 2025 net loss attributable to parent company reaching 398 million yuan (approximately $55 million), while revenue declined 18.99% year-over-year to 1.819 billion yuan. The company attributed the decline to domestic vaccine procurement policies, intensified industry competition, and consumer vaccine hesitancy.
The nine-valent HPV vaccine, which launched in 2025 as China’s first domestically developed nine-valent HPV vaccine and the world’s second, completed its first inoculation on September 9, 2025. However, the company stated in its financial report that the vaccine “remains in the market entry phase and has not yet generated scaled profit contributions,” failing to offset losses from inventory disposal of bivalent HPV vaccine and government procurement price reductions. The vaccine segment revenue fell 24.63% year-over-year to 457 million yuan, with gross margin declining 43.18 percentage points.
The diagnostic segment generated 1.309 billion yuan in revenue, down 18.65% year-over-year, impacted by procurement price cuts and medical insurance policy adjustments. International revenue, however, surged 90.85% to 412 million yuan, driven by substantial growth in bivalent HPV vaccine exports. Wantai Biotech is advancing nine-valent HPV vaccine WHO prequalification preparations and has initiated Phase 3 clinical trials for male populations, with the first participant enrolled.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
Related Articles
Whale Trader Dr. Profit Shorts $1M in Altcoins Across 100 Positions
Gate News message, April 21 — Prominent whale trader Dr. Profit has deployed $1 million in a bearish bet against altcoins, spreading the capital across 100 separate positions with independent margins to limit liquidation risk to 1% per position.
Dr. Profit also holds a $120,000 BTC short and
GateNews3m ago
Revolut Weighs Future IPO, Flexes India's Beta Launch
The UK-based neobank could go public in the next two years, according to statements of its co-founder and CEO, Nik Storonsky. During its latest funding round conducted in October, the firm reached a valuation of $75 billion, up from $45 billion before.
Key Takeaways:
Revolut CEO Nik Storonsky
Coinpedia31m ago
William Hill Parent Evoke in £225M Bally's Intralot Sale Discussions
William Hill and 888 parent Evoke confirmed Monday it is in takeover discussions with Bally’s Intralot at 50 pence per share, valuing the FTSE 250-listed betting group at £225.3 million ($303.9 million).
Key Takeaways:
Evoke confirmed 50p-per-share Bally’s Intralot offer valuing group at £225.3M.
Coinpedia48m ago
ProCap Financial Partners with Kalshi to Launch AI-Powered Prediction Market Research Service
Gate News message, April 21 — ProCap Financial, founded by crypto entrepreneur Anthony Pompliano, has partnered with Kalshi, a prediction market operator, to launch a research service focused on prediction market analysis. The service leverages Kalshi's data pipeline and ProCap's AI agents to
GateNews53m ago
JPMorgan Raises S&P 500 Target to 7,600 on AI Optimism
Abstract: JPMorgan strategists lift their S&P 500 year-end target to 7,600 from 7,200 on renewed AI optimism, anticipating higher levels this year as tech and AI prospects improve.
Summary: JPMorgan raises S&P 500 year-end target to 7,600 from 7,200, citing renewed AI optimism; at 7,109, about 7% upside, with potential gains fueled by AI-driven growth.
GateNews1h ago
TradFi Rise Alert: UNH (UnitedHealth) Rises Over 6%
Gate News: According to the latest Gate TradFi data, UNH (UnitedHealth) has surged by 6% in a short period. Current volatility is significantly higher than recent averages, indicating increased market activity.
GateNews2h ago
